TipRanks
Advertisement
Advertisement

DE:BM8 Stock Latest News

BioMarin names Cara Bauer as Chief People Officer
The FlyBioMarin names Cara Bauer as Chief People Officer
2d ago
BMRN
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
PremiumThe Fly
BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA
6d ago
BMRN
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
PremiumCompany Announcements
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
7d ago
8K
BMRN
BioMarin price target lowered to $97 from $98 at BMO Capital
PremiumThe Fly
BioMarin price target lowered to $97 from $98 at BMO Capital
23d ago
BMRN
BioMarin ends VOXZOGO development for Noonan syndrome
PremiumCompany Announcements
BioMarin ends VOXZOGO development for Noonan syndrome
23d ago
8K
BMRN
BioMarin to discontinue development of Voxzogo for children with Noonan syndrome
PremiumThe FlyBioMarin to discontinue development of Voxzogo for children with Noonan syndrome
23d ago
BMRN
BioMarin Pharmaceutical Adds Independent Director to Board
Premium
Company Announcements
BioMarin Pharmaceutical Adds Independent Director to Board
24d ago
8K
BMRN
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
Premium
The Fly
BioMarin names Robert Plenge, M.D., Ph.D., to board of directors
24d ago
BMY
BMRN
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
PremiumRatings
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
28d ago
BMRN
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
PremiumThe Fly
BioMarin reports new data from Phase 3 CANOPY-HCH-3 study
29d ago
BMRN
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
PremiumThe Fly
Ascendis Pharma price target raised to $312 from $304 at Oppenheimer
1M ago
ASND
BMRN
BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
PremiumCompany Announcements
BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics
1M ago
8K
BMRN
BioMarin completes agreement to acquire Alesta Therapeutics
PremiumThe FlyBioMarin completes agreement to acquire Alesta Therapeutics
1M ago
BMRN
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
Premium
Ratings
Balanced Upside and Execution Risks Lead Richter to Maintain Hold on BioMarin After ASND Settlement and Voxzogo Expansion Plans
1M ago
BMRN
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
Premium
Ratings
BioMarin Settlement with Ascendis Clears Legal Overhang; Analyst Reaffirms Buy Rating and Maintains $114 Price Target
1M ago
BMRN
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
PremiumThe Fly
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
1M ago
ASND
BMRN
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
PremiumThe Fly
Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley
1M ago
ASND
BMRN
BioMarin price target raised to $90 from $88 at Piper Sandler
PremiumThe Fly
BioMarin price target raised to $90 from $88 at Piper Sandler
1M ago
ASND
BMRN
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
PremiumRatings
BioMarin Kept at Hold as YUVIWEL Royalties Lift DCF and Price Target Rises from $59 to $60 Amid VOXZOGO Headwinds
1M ago
BMRN
Analyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
PremiumRatingsAnalyst Sees BioMarin Undervalued After Ascendis Settlement, Modestly Raising Price Target to $105
1M ago
BMRN
H.C. Wainwright trims Ascendis target, says litigation overhang removed
Premium
The Fly
H.C. Wainwright trims Ascendis target, says litigation overhang removed
1M ago
ASND
BMRN
BioMarin price target raised to $105 from $104 at Jefferies
Premium
The Fly
BioMarin price target raised to $105 from $104 at Jefferies
1M ago
ASND
BMRN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >